Umckaloabo

Other Name(s):

African Geranium, EPs 7630, Geranien, Geranio Sudafricano, Geranium, Géranium d'Afrique, Géranium d'Afrique du Sud, Géranium du Cap, Geranium Root, Ikhubalo, Icwayiba, i-Yeza lezikali, Kalwerbossi, Khoaara e Nyenyane, Pelargonien, Pelargonio Sudafricano, Pelargonium Root, Pélargonium d'Afrique, Pélargonium du Cap, Pelargonium sidoides, Rabas, Rabassam, Racine de Géranium, Racine de Pélargonium, South African Geranium, Uvendle.

Overview

Umckaloabo is a flowering plant that is native to South Africa, as the name suggests. Its roots are used for medicine.

Umckaloabo was first promoted in Britain in 1897 as a treatment for tuberculosis. It was marketed by Charles Henry Stevens and was known as “Stevens' Cure.” It fell out of favor when antibiotics were developed in the mid-1900s.

These days umckaloabo is used for upper respiratory infections including bronchitis, sinusitis, sore throat, tonsillitis, and the common cold. It is also used for sexually transmitted diseases including herpes and gonorrhea. Other uses include treatment of dysentery and diarrhea.

How does it work?

Umckaloabo is usually used for infections such as bronchitis and sinus infection. Researchers think that it might work by killing bacteria or preventing bacteria from attaching to surfaces within the body. Umckaloabo might also increase the body's normal response to infection.

Uses & Effectiveness

Likely Effective for...

  • Bronchitis. Research shows that adults and children with bronchitis who start taking a specific Umckaloabo extract (Umckaloabo, EPs 7630, Schwabe GmBh, Germany) within 48 hours of feeling sick have fewer symptoms after 7 days of treatment. Some studies have also used extracts in tablet form. However, the tablets seemed to work only for adults, not children.

Possibly Effective for...

  • Sore throat and swollen tonsils (tonsillopharyngitis). When given to children experiencing sore throat and swollen tonsils, Umckaloabo extract seems to significantly reduce pain and difficulty swallowing after 4 days of treatment.

Insufficient Evidence to Rate Effectiveness for...

  • Common cold. Early research suggests that taking Umckaloabo extract three times per day can help reduce symptoms and clear up the common cold after 10 days of treatment.
  • Nasal swelling (sinusitis). Early research suggests that taking Umckaloabo extract three times per day helps reduce symptoms and clear up sinusitis after 21 days of treatment.
  • Tuberculosis.
  • Diarrhea.
  • Other conditions.
More evidence is needed to rate Umckaloabo for these uses.

Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, and Insufficient Evidence to Rate (detailed description of each of the ratings).

SLIDESHOW

Vitamin D Deficiency: How Much Vitamin D Is Enough? See Slideshow

Side Effects

Umckaloabo extract is LIKELY SAFE when taken by mouth for up to 3 weeks. There is not enough information to know if it is safe when taken for longer periods of time. Some people who take it can experience stomach upset. Some people have had allergic reactions to Umckaloabo.

Special Precautions & Warnings

Pregnancy and breast-feeding: There is not enough reliable information about the safety of taking Umckaloabo if you are pregnant or breast-feeding. Stay on the safe side and avoid use.

Children: Umckaloabo is POSSIBLY SAFE when taken by mouth for up to one week. There is not enough information to know if it is safe when taken for longer periods of time.

“Auto-immune diseases” such as multiple sclerosis (MS), lupus (systemic lupus erythematosus, SLE), rheumatoid arthritis (RA), or other conditions: Umckaloabo might cause the immune system to become more active. This could increase the symptoms of auto-immune diseases. If you have one of these conditions, it's best to avoid using Umckaloabo.

Bleeding disorders: A chemical in Umckaloabo, called coumarin, might slow blood clotting and increase bleeding. In theory, Umckaloabo might make bleeding disorders worse.

Surgery: A chemical in Umckaloabo, called coumarin, might slow blood clotting. In theory, Umckaloabo might increase the risk for bleeding during surgical procedures. Stop using Umckaloabo at least 2 weeks before a scheduled surgery.

Interactions


Medications that decrease the immune system (Immunosuppressants)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.

Umckaloabo might increase the activity of the immune system. Taking Umckaloabo along with some medications that decrease the immune system's activity might decrease the effectiveness of these medications.

Some medications that decrease the immune system's activity include azathioprine (Imuran), basiliximab (Simulect), cyclosporine (Neoral, Sandimmune), daclizumab (Zenapax), muromonab-CD3 (OKT3, Orthoclone OKT3), mycophenolate (CellCept), tacrolimus (FK506, Prograf), sirolimus (Rapamune), prednisone (Deltasone, Orasone), corticosteroids (glucocorticoids), and others.


Medications that slow blood clotting (Anticoagulant / Antiplatelet drugs)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.

A chemical in Umckaloabo, called coumarin, might slow blood clotting. Although the risk seems small, taking Umckaloabo along with medications that also slow blood clotting might increase the chances of bruising and bleeding.

Some medications that slow blood clotting include aspirin; clopidogrel (Plavix); nonsteroidal anti-inflammatory drugs (NSAIDs) such as diclofenac (Voltaren, Cataflam, others), ibuprofen (Advil, Motrin, others), naproxen (Anaprox, Naprosyn, others); dalteparin (Fragmin); enoxaparin (Lovenox); heparin; warfarin (Coumadin); and others.

QUESTION

Next to red peppers, you can get the most vitamin C from ________________. See Answer

Dosing

The following doses have been studied in scientific research:

BY MOUTH:

  • For bronchitis: 30 drops (about 1.5 mL) three times daily or 10-30 mg tablets three times daily of a specific extract of Umckaloabo (Umckaloabo, EPs 7630, Schwabe GmBh, Germany) for 7 days. In children age 7-12 years, 20 drops of this extract three times daily. In children age 6 years or less, 10 drops of this extract three times daily. Some studies have not found the tablet formulation to work in children.
  • For sore throat and swollen tonsils in children age 6-10 years: 20 drops of a specific extract of Umckaloabo (Umckaloabo, EPs 7630, Schwabe GmBh, Germany) three times daily (about 3 mL/day) for 7 days.

Health Solutions From Our Sponsors

Reviewed on 6/14/2021
References

Beil, W. and Kilian, P. EPs 7630, an extract from Pelargonium sidoides roots inhibits adherence of Helicobacter pylori to gastric epithelial cells. Phytomedicine 2007;14 Suppl 6:5-8. View abstract.

Chuchalin, A. G., Berman, B., and Lehmacher, W. Treatment of acute bronchitis in adults with a pelargonium sidoides preparation (EPs 7630): a randomized, double-blind, placebo-controlled trial. Explore.(NY) 2005;1(6):437-445. View abstract.

de Boer, H. J., Hagemann, U., Bate, J., and Meyboom, R. H. Allergic reactions to medicines derived from Pelargonium species. Drug Saf 2007;30(8):677-680. View abstract.

Fukuda, H., Kishii, R., Takei, M., and Hosaka, M. Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae. Antimicrob.Agents Chemother. 2001;45(6):1649-1653. View abstract.

Koch E, Lanzendörfer-Goossens Wohn C. Stimulation of interferon (IFN)-â-synthesis and natural killer (NK) cell activity by an aqueous-ethanolic extract from roots of Pelargonium sidoides (Umckaloabo). Naunyn-Schmiederberg's Arch Pharmacol 2002;365 (suppl 1):R75.

Kolodziej, H., Burmeister, A., Trun, W., Radtke, O. A., Kiderlen, A. F., Ito, H., Hatano, T., Yoshida, T., and Foo, L. Y. Tannins and related compounds induce nitric oxide synthase and cytokines gene expressions in Leishmania major-infected macrophage-like RAW 264.7 cells. Bioorg.Med Chem 12-1-2005;13(23):6470-6476. View abstract.

Lizogub, V. G., Riley, D. S., and Heger, M. Efficacy of a pelargonium sidoides preparation in patients with the common cold: a randomized, double blind, placebo-controlled clinical trial. Explore.(NY) 2007;3(6):573-584. View abstract.

Matthys, H. and Heger, M. Treatment of acute bronchitis with a liquid herbal drug preparation from Pelargonium sidoides (EPs 7630): a randomised, double-blind, placebo-controlled, multicentre study. Curr.Med Res Opin. 2007;23(2):323-331. View abstract.

Matthys, H., Eisebitt, R., Seith, B., and Heger, M. Efficacy and safety of an extract of Pelargonium sidoides (EPs 7630) in adults with acute bronchitis. A randomised, double-blind, placebo-controlled trial. Phytomedicine 2003;10 Suppl 4:7-17. View abstract.

Neugebauer, P., Mickenhagen, A., Siefer, O., and Walger, M. A new approach to pharmacological effects on ciliary beat frequency in cell cultures--exemplary measurements under Pelargonium sidoides extract (EPs 7630). Phytomedicine 2005;12(1-2):46-51. View abstract.

Schulz, V. Liquid herbal drug preparation from the root of Pelargonium sidoides is effective against acute bronchitis: results of a double-blind study with 124 patients. Phytomedicine 2007;14 Suppl 6:74-75. View abstract.

Trun, W., Kiderlen, A. F., and Kolodziej, H. Nitric oxide synthase and cytokines gene expression analyses in Leishmania-infected RAW 264.7 cells treated with an extract of Pelargonium sidoides (Eps 7630). Phytomedicine 2006;13(8):570-575. View abstract.

Wittschier, N., Lengsfeld, C., Vorthems, S., Stratmann, U., Ernst, J. F., Verspohl, E. J., and Hensel, A. Large molecules as anti-adhesive compounds against pathogens. J Pharm Pharmacol. 2007;59(6):777-786. View abstract.

Agbabiaka TB, Guo R, Ernst E. Pelargonium sidoides for acute bronchitis. A systematic review and meta-analysis. Phytomedicine 2008;15:378-85. View abstract.

Bereznoy VV, Riley DS, Wassmer G, Heger M. Efficacy of extract of Pelargonium sidoides in children with acute non-group A beta-hemolytic streptococcus tonsillopharyngitis: a randomized, double-blind, placebo-controlled trial. Altern Ther Health Med 2003;9:68-79. View abstract.

Brendler T, van Wyk BE. A historical, scientific and commercial perspective on the medicinal use of Pelargonium sidoides (Geraniaceae). J Ethnopharmacol 2008;119:420-33. View abstract.

Chuchalin AG, Berman B, Lehmacher W. Treatment of acute bronchitis in adults with a pelargonium sidoides preparation (EPs 7630): A randomized, double-blind, placebo-controlled trial. Explore 2005;1:437-45.

Conrad A, Hansmann C, Engels I, et al. Extract of Pelargonium sidoides (EPs 7630) improves phagocytosis, oxidative burst, and intracellular killing of human peripheral blood phagocytes in vitro. Phytomedicine 2007;14 Suppl 6:46-51. View abstract.

Conrad A, Jung I, Tioua D, et al. Extract of Pelargonium sidoides (EPs 7630) inhibits the interactions of group A-streptococci and host epithelia in vitro. Phytomedicine 2007;14 Suppl 6:52-9. View abstract.

Kayser O, Kolodziej H, Kiderlen AF. Immunomodulatory principles of Pelargonium sidoides. Phytother Res 2001;15:122-6. View abstract.

Kayser O, Kolodziej H. Antibacterial activity of extracts and constituents of Pelargonium sidoides and Pelargonium reniforme. Planta Med 1997;63:508-10. View abstract.

Koch E, Biber A. Treatment of rats with the Pelargonium sidoides extract EPs 7630 has no effect on blood coagulation parameters or on the pharmacokinetics of warfarin. Phytomedicine 2007;14 Suppl 6:40-5. View abstract.

Kolodziej H, Kayser O, Radtke OA, et al. Pharmacological profile of extracts of Pelargonium sidoides and their constituents. Phytomedicine 2003;10 Suppl 4:18-24. View abstract.

Kolodziej H, Kiderlen AF. In vitro evaluation of antibacterial and immunomodulatory activities of Pelargonium reniforme, Pelargonium sidoides and the related herbal drug preparation EPs 7630. Phytomedicine 2007;14 Suppl 6:18-26. View abstract.

Matthys H, Heger M. EPs 7630-solution--an effective therapeutic option in acute and exacerbating bronchitis. Phytomedicine 2007;14 Suppl 6:65-8. View abstract.

Matthys H, Kamin W, Funk P, Heger M. Pelargonium sidoides preparation (EPs 7630) in the treatment of acute bronchitis in adults and children. Phytomedicine 2007;14 Suppl 6:69-73. View abstract.

Matthys H, Lizogub VG, Malek FA, Kieser M. Efficacy and tolerability of EPs 7630 tablets in patients with acute bronchitis: a randomised, double-blind, placebo-controlled dose-finding study with a herbal drug preparation from Pelargonium sidoides. Curr Med Res Opin 2010;26:1413-22. View abstract.

Schnitzler P, Schneider S, Stintzing FC, et al. Efficacy of an aqueous Pelargonium sidoides extract against herpesvirus. Phytomedicine 2008;15:1108-16. View abstract.

Schotz K, Noldner M. Mass spectroscopic characterisation of oligomeric proanthocyanidins derived from an extract of Pelargonium sidoides roots (EPs 7630) and pharmacological screening in CNS models. Phytomedicine 2007;14 Suppl 6:32-9. View abstract.

Seidel V, Taylor PW. In vitro activity of extracts and constituents of Pelagonium against rapidly growing mycobacteria. Int J Antimicrob Agents 2004;23:613-9. View abstract.

Timmer A, Günther J, Rücker G, et al. Pelargonium sidoides extract for acute respiratory tract infections. Cochrane Database Syst Rev 2008;(3):CD006323. View abstract.

Wittschier N, Faller G, Hensel A. An extract of Pelargonium sidoides (EPs 7630) inhibits in situ adhesion of Helicobacter pylori to human stomach. Phytomedicine 2007;14:285-8. View abstract.

Health Solutions From Our Sponsors